Member Profile

ACT Genomics is a world-leading cancer solution provider. We offer precision medicine services in Taiwan, Singapore, Hong Kong, and Japan. We combine our expertise in tumor biology, cancer genomics, and bioinformatics to provide treatment guidelines for solid tumors, relapse, drug resistance, as well as cancer monitoring, risk assessment, and immunotherapy evaluation. Through cutting-edge next-generation sequencing (NGS) platforms, CAP/LDTS-accredited laboratory, bioinformatics analysis, and comprehensive service offerings, we seek to convert every cancer patient’s genetic information into actionable solutions.

Company Milestones

   2014 ACT Genomics was founded and opened ACT Genomics NGS laboratory
   2015 Established ACT Genomics Singapore branch
   2016 Received CAP Accreditation
   2016 Granted the Symbol of National Quality Award in the Biotechnology Service Category
   2016 Established ACT Genomics Hong Kong branch and Shanghai branch
   2017 ACT Genomics Received 2017 Frost & Sullivan Asia Pacific Molecular Diagnostics Product Line Strategy Leadership Award
   2017 Established ACT Genomics Japan branch
   2018 ACT Genomics joins TMB Harmonization Project to standardize the calculation of tumor mutational burden
   2018 Canon Medical System Corporation officially acquired ACT Genomics’ joint venture company in Japan, ACTmed
   2019 ACT Genomics Establishes NGS Laboratory to Offer Comprehensive Cancer Genomic Profiling Service in Japan
   2019 ACT Genomics opened its third Next Generation Sequencing laboratory in Asia at the Hong Kong Science Park
   2020 ACT Genomics is the first to receive approval for laboratory-developed NGS tests and services (LDTS) in Taiwan
   2020 Acquires ISO/IEC 27001 certification
   2021 ACT Genomics completes acquisition of MC Diagnostics
   2021 CerbACT Asia – a joint venture between ACT Genomics and Cerba Research – is formed to establish a new and top-notched facility in Taipei
   2021 ACT Genomics acquires Sanomics